Sustained Remission Following Limited Dupilumab Exposure in Refractory Eosinophilic Esophagitis
Abstract
Eosinophilic esophagitis (EoE) is a type 2 immune-mediated esophageal disorder that can be refractory to standard therapy. We present a case of a 49-year-old woman with asthma, chronic sinusitis, and nasal polyposis diagnosed with EoE refractory to proton pump inhibitors, dietary modification, and swallowed topical corticosteroids. She was treated with dupilumab in 2023 but discontinued it after 3 months due to side effects. Subsequent esophagogastroduodenoscopies demonstrated sustained histologic and endoscopic remission up to October 2025 (26 months later), after which recurrence of disease was confirmed. This case highlights 2-year sustained remission following limited exposure to dupilumab in refractory EoE.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.